.jpg)
Response Evaluation Criteria in PSMA-imaging (RECIP)
Novel evidence-based framework for response evaluation in metastatic prostate cancer using PSMA PET imaging.
Response Evaluation Criteria In PSMA-PET/CT (RECIP) is a standardized evidence-based framework developed by an interdisciplinary team of investigators to evaluate efficacy of systemic therapies in prostate cancer. RECIP 1.0 introduced for the first time the novel concept of combining responses in total tumor volume with status of new lesions. RECIP 1.0 can be applied on PSMA-PET/CT scans to monitor therapeutic efficacy in prostate cancer.
RECIP combines changes in total tumor volume and status of new lesions and can be calculated dual-way: Visual RECIP and Quantitative RECIP.
Visual RECIP: Changes in total volume are evaluated by visual reads of nuclear medicine physicians or radiologists, and are combined with status of new lesions to calculate RECIP.
Quantitative RECIP: Changes in total tumor volume are evaluated quantitatively using tumor segmentation software and combined with status of new lesions to calculate RECIP.
RECIP 1.0 Definition
RECIP Publications
Educational Platform
RECIP Educational Platform was developed to offer free training for healthcare professionals who intend to use RECIP 1.0 criteria in their research, daily practice, or clinical trials.
PROMISE V2 framework
The prostate cancer molecular imaging standardized evaluation (PROMISE) criteria version 1 have been proposed as a comprehensive framework for whole-body staging to describe the prostate cancer disease extent on PSMA-PET.
PROMISE version 2 (V2) were recently published and provide harmonized TNM categories, improved assessment of local disease, and updated PSMA-expression score. A reporting template for response assessment in clinical trials by defining qualitative and quantitative imaging parameters to be recorded. The PROMISE V2 templates can serve as a basis for current and future response assessment frameworks.
Insights from Our Collaborators
RECIP is a novel method to monitor drug efficacy in prostate cancer and it is truly transformative. It has changed our clinical practice.
We have been using RECIP 1.0 in our daily practice to evaluate treatment response in prostate cancer using PSMA-PET/CT and our clinicians are very satisfied with it.
RECIP 1.0 has changed our practice. It allows us to evaluate response on PSMA-PET/CT in a standardized way and make an evidence-based recommendation to our urologists and medical oncologists.
Supported by our valued partners around the globe
The ProstateCancer Foundation (PCF) is the world's leading philanthropic organization dedicated to funding life-saving prostate cancer research. Development of RECIP has been funded by the PCF Young Investigator Award 21YOUN18.
PI: Andrei Gafita
Enter your email to receive the latest updates and features from RECIP - Criteria. Stay informed on advancements in PSMA-PET/CT treatment response evaluation to enhance your clinical practice and research.
